Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 20/20 | 0.45 |
| ▸ | CCNY | Q8ND76 | 19/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007794 | 0.94 | CDK14 (0.47) | CDK14CCNY | |
| SCHEMBL8262598 | 0.90 | CDK14 (0.46) | CDK14CCNY | |
| SCHEMBL13993668 | 0.89 | CDK14 (0.46) | CDK14CCNY | |
| SCHEMBL2030754 | 0.89 | CDK14 (0.49) | CDK14CCNY | |
| SCHEMBL2031219 | 0.89 | CDK14 (0.51) | CDK14CCNY | |
| SCHEMBL8261496 | 0.88 | CDK14 (0.46) | CDK14CCNY | |
| SCHEMBL8262073 | 0.86 | CDK14 (0.47) | CDK14CCNY | |
| SCHEMBL8262985 | 0.86 | CDK14 (0.47) | CDK14CCNY | |
| SCHEMBL13993667 | 0.85 | CDK14 (0.46) | CDK14CCNY | |
| SCHEMBL13993657 | 0.85 | CDK14 (0.44) | CDK14CCNY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CDK14 8/4885CCNY 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.